论文部分内容阅读
子宫内膜异位症(EMs)是育龄妇女的常见病,保守性手术后复发率高,有必要予以术后药物治疗。目前的术后用药多样,但几乎都表现为用药依赖,往往需要数年甚至更久的维持用药。口服避孕药、孕激素因其经济、方便,不良反应少,可作为术后治疗的一线选择;而促性腺激素释放激素类似物长期用药的益处相比于其昂贵的医疗费用及不良反应优势并不明显,因而与达那唑、孕三烯酮等作为二线用药。而左炔诺孕酮宫内缓释系统特别适用于合并子宫肌腺病的EMs患者。另外免疫调节、基因靶向治疗为其提供了新的治疗思路。
Endometriosis (EMs) is a common disease in women of childbearing age, the recurrence rate after conservative surgery is high, it is necessary to be postoperative drug treatment. The current postoperative drug diversification, but almost always manifested as drug dependence, often require years or even longer maintenance medication. Oral contraceptives, progesterone because of its economy, convenience, fewer adverse reactions, can be used as a first-line treatment options; and gonadotropin-releasing hormone analogues long-term medication benefits compared to its expensive medical costs and adverse reaction and Not obvious, so with danazol, gestrinone as second-line medication. The levonorgestrel intrauterine release system is particularly suitable for patients with adenomyosis EMs. In addition, immunomodulatory and gene-targeted therapies provide new therapeutic ideas.